- 1 in 35 preemies develops a heart issue linked to high death risk
- Early meds help most, but youngest babies still face biggest dangers
- Not a cure — but a step toward smarter, faster care in NICUs
This study reveals which premature babies benefit most from early heart treatment — and who needs even better options.
It starts with a faint murmur on a stethoscope. A preemie breathes fast. Oxygen levels dip. In the NICU, alarms hum softly in the background. For parents, every beep feels heavy. Often, the cause is a tiny heart passage that never closed after birth — a condition called PDA.
That open passage can strain the heart and lungs. And for the tiniest babies, it can be life-threatening.
PDA — short for patent ductus arteriosus — affects thousands of preemies every year. It’s normal before birth. But after delivery, that small blood vessel between two heart vessels should close on its own.
In premature babies, it often doesn’t.
The smaller and earlier the baby, the less likely it closes. And when it stays open, blood flows where it shouldn’t. It’s like a traffic jam in the heart’s plumbing.
This can lead to breathing problems, heart failure, or even death.
About 1 in 35 preemies in this study had PDA. Most were very small — under 3 pounds at birth. Nearly all struggled to breathe, mostly due to underdeveloped lungs.
Doctors have treatments. But not every baby responds the same. And until now, it’s been hard to know who will improve — and who won’t.
The surprising shift
For years, doctors waited for clear symptoms before treating PDA. The thinking? Avoid unnecessary drugs in fragile babies.
But waiting may do more harm than good.
This study shows that early treatment — with common medicines like ibuprofen or IV acetaminophen — helped most babies. Within three days, over 80% had closed the passage. And 77% showed clear clinical improvement.
Here’s the catch: the youngest babies — those born before 28 weeks — still faced much higher risks.
Their tiny bodies responded less to meds. And their chance of dying was five times higher than older preemies.
What scientists didn’t expect
The data revealed two strong predictors of success: being born at or after 28 weeks, and whether the mother received steroid shots before delivery.
Babies who got antenatal steroids were more likely to respond to treatment. So were those closer to full term.
That’s important. It means some risks can be reduced — even before birth.
Steroids help speed up lung development. But they may also help the heart mature faster. Think of it like jump-starting a car on a cold morning — the engine turns over more easily.
Imagine the heart as a house with pipes and valves. Before birth, one pipe — the ductus arteriosus — lets blood skip the lungs (since the baby gets oxygen from mom).
After birth, that pipe should seal shut.
In preemies, it often stays open. It’s like leaving a faucet running in a small room — eventually, the floor floods.
Medicines like ibuprofen or IV acetaminophen help close the faucet. They reduce swelling and signal the body to seal the passage.
But in the tiniest babies, the pipe walls are too weak or immature to respond.
That’s why timing and maturity matter so much.
Researchers looked back at 60 preemies with PDA over four years at one major hospital. All were born early, with an average age of 29 weeks. Most weighed just over 2.5 pounds.
All received medicine to close the duct. Doctors tracked who improved and who didn’t — using exams and heart scans.
Data was pulled from medical records. No new treatments were tested.
Most babies responded well. Over 80% had the duct close after first treatment. Nearly three out of four showed clear signs of getting better — easier breathing, stable heart rates.
But survival told a starker story. Overall, 35% of babies with PDA died. And among those born before 28 weeks, death rates were far higher.
The good news? Babies who responded to meds — either clinically or on heart scans — were much more likely to survive.
Closing the duct wasn’t just a number on a screen. It meant real survival benefit.
This doesn’t mean this treatment is available yet.
But there’s a catch.
Not all babies were included. Some with severe issues may have been too sick to treat. Others may have been missed.
And this study looked at just one hospital. Results might differ elsewhere.
Also, while IV acetaminophen worked for some, it’s not yet standard everywhere. More research is needed to confirm the best drug and dose.
This study fits a growing trend: treat earlier, act faster. It adds hard data to what many NICU teams already suspect — that timing and baby maturity are key.
It also supports using heart scans more often in high-risk babies — not just to diagnose, but to guide treatment.
If you’re a parent of a preemie, this isn’t a new treatment — it’s a clearer picture of what works.
No new drugs are available today. But doctors may now feel more confident treating PDA earlier — especially in babies born after 28 weeks or whose moms got steroid shots.
Talk to your care team. Ask: Was PDA checked? Was treatment given? What signs show improvement?
Early action may make a difference.
More studies are needed — especially ones that test treatments head-to-head and follow babies longer. Researchers need to confirm which babies benefit most from early meds — and which need other options.
For now, this study helps sharpen the tools doctors already have. It won’t change care overnight. But it’s a step toward smarter, safer decisions in the NICU.